标题
How Taxol/paclitaxel kills cancer cells
作者
关键词
-
出版物
MOLECULAR BIOLOGY OF THE CELL
Volume 25, Issue 18, Pages 2677-2681
出版商
American Society for Cell Biology (ASCB)
发表日期
2014-09-12
DOI
10.1091/mbc.e14-04-0916
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles
- (2014) L. M. Zasadil et al. Science Translational Medicine
- Intravital FRET Imaging of Tumor Cell Viability and Mitosis during Chemotherapy
- (2013) Aniek Janssen et al. PLoS One
- Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
- (2012) E. Komlodi-Pasztor et al. CLINICAL CANCER RESEARCH
- The Spindle Assembly Checkpoint
- (2012) Pablo Lara-Gonzalez et al. CURRENT BIOLOGY
- Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore
- (2012) Emily A. Foley et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel
- (2012) Uchenna O. Njiaju et al. Pharmacogenetics and Genomics
- Up-regulation of the mitotic checkpoint component Mad1 causes chromosomal instability and resistance to microtubule poisons
- (2012) S. D. Ryan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of Mitosis and Antimitotic Drug Responses in Tumors by In Vivo Microscopy and Single-Cell Pharmacodynamics
- (2011) J. D. Orth et al. CANCER RESEARCH
- The proliferation rate paradox in antimitotic chemotherapy
- (2011) Timothy J. Mitchison MOLECULAR BIOLOGY OF THE CELL
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Mitosis is not a key target of microtubule agents in patient tumors
- (2011) Edina Komlodi-Pasztor et al. Nature Reviews Clinical Oncology
- Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest
- (2011) P Russell et al. ONCOGENE
- Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
- (2010) A. Chakravarty et al. CANCER RESEARCH
- Intravenous Paclitaxel Is Specifically Retained in Human Gynecologic Carcinoma Tissues In Vivo
- (2010) Hisato Koshiba et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Welcome to a new kind of tension: translating kinetochore mechanics into a wait-anaphase signal
- (2010) Thomas J. Maresca et al. JOURNAL OF CELL SCIENCE
- Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
- (2010) Nicolai Juul et al. LANCET ONCOLOGY
- Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
- (2009) Lajos Pusztai et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells
- (2009) Aniek Janssen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs
- (2008) Karen E. Gascoigne et al. CANCER CELL
- Cell Type Variation in Responses to Antimitotic Drugs that Target Microtubules and Kinesin-5
- (2008) J. Shi et al. CANCER RESEARCH
- Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
- (2008) J. D. Orth et al. MOLECULAR CANCER THERAPEUTICS
- Live-cell analysis of mitotic spindle formation in taxol-treated cells
- (2008) Jessica E. Hornick et al. CELL MOTILITY AND THE CYTOSKELETON
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started